IMCIVREE Gains EU Momentum for Rare Obesity Disorder
Boston, March 26, 2026 In a significant advancement for rare disease therapeutics, Rhythm Pharmaceuticals has received a positive opinion...
Rhythm Pharmaceuticals
Advertisement
FDA Approves Rhythm Pharmaceuticals’ IMCIVREE for Acquired Hypothalamic Obesity
BOSTON, March 19, 2026 Rhythm Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Imcivree (setmelanotide) for...
Rhythm Pharmaceuticals Presents Four New Datasets at ObesityWeek® 2025
Boston, November 10, 2025 — Rhythm Pharmaceuticals, Inc. has announced the presentation of four pivotal datasets at ObesityWeek® 2025,...
Advertisement
